NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Monopar Therapeutics Inc. (MNPR) Stock Analysis

Monopar Therapeutics Inc. (MNPR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MNPR

$72.35

−$1.88 (−2.53%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MNPR with… →

MNPR Key Statistics

As of Oct 21, 2026
Trading
Open
$74.03
Previous Close
$74.23
Day's Range
70.95–74.78
52-Week Range
50.07–124.82
Volume
76.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.51
Valuation
Market Cap
$485.63M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.20
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$13.72M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.71M
1-Year Return
−6.83%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
201.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MNPR closed at $72.35, −6.83% over 1 year.

Monopar Therapeutics Inc. (MNPR) has a market capitalization of $485.63M.

In fiscal 2025, MNPR reported revenue of $0.00.

MNPR Stock Return by Calendar Year

Monopar Therapeutics Inc. (MNPR) return since Dec 2019: what $10,000 became

1 year
$10,000 $9,317
−6.83%
5 years
$10,000 $30,146
+201.46%
Since Dec 2019
$10,000 $5,460
−45.40%

If you had invested $10,000 in Monopar Therapeutics Inc. (MNPR) at the close on December 19, 2019, the earliest close on record here, it would have been worth $5,460 at the close on October 21, 2026: −45.40% in total, −8.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.80%
2025+196.82%
2024+1,194.12%
2023−85.65%
2022−26.17%
2021−47.55%
2020−63.13%
2019 (partial year)−37.36%

As of October 21, 2026.

MNPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$13.72M—
2024$0.00−$15.59M—
2023$0.00−$8.40M—
2022$0.00−$10.52M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$16.70M−$13.72M—
2024$0.00—−$16.16M−$15.59M—
2023$0.00—−$8.83M−$8.40M—
2022$0.00—−$10.54M−$10.52M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Monopar Therapeutics Inc. (MNPR) carries a market capitalisation of $485.63M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 22.

The 52-week range on file runs from $50.07 to $124.82. The most recent close on file for MNPR is $72.35, dated October 21, 2026. That is −$1.88 (−2.53%) against the previous close. The latest close sits 44.5% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $13.72M. Trailing earnings per share are −2.2.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.51. Annualized volatility over the trailing 6 years is 272.21%. The trailing one-year total return is −6.83%. Measured over 5 years, that is +24.69% a year compounded.

Growth & Income

The record shows no dividend for MNPR.

2026 is still running; the total return is +10.80% year to date. The strongest complete calendar year on file is 2024 at +1,194.12%; the weakest is 2023 at −85.65%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Monopar Therapeutics Inc. (MNPR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Monopar Therapeutics Inc. MNPR $485.63M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Monopar Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Visit website →